Abstract
Recent reports from phase III trials (PARADIGM, DECIDE) did not demonstrate a survival benefit with the addition of IC to CRT for head and neck squamous cell carcinoma, however these trials did not specifically address patients with OPSCC. We analyzed our experience treating OPSCC to determine if this subgroup of patients benefits from the addition of IC with docetaxel, cisplatin, 5-fluorouracil (TPF) to platinum based CRT, which is the current standard of care for locoregionally advanced OPSCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
